A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
Multiple Myeloma|Relapsed Cancer|Refractory Multiple Myeloma|Adult Disease|Hematologic Diseases
DRUG: ANV419|DRUG: Lenalidomide with low-dose dexamethasone|DRUG: Daratumumab
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) with ANV419 monotherapy, Day 1 up to 12 months|Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) with ANV419 in combination with lenalidomide plus low-dose dexamethasone, Day 1 up to 12 months|Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) with ANV419 in combination with daratumumab, Day 1 up to 12 months
Serum concentration of ANV419 in blood, Day 1 up to 12 months|Impact of ANV419 on the expression of markers of PBMC lineage in blood, Day 1 up to 12 months|Levels of specific anti-ANV419 antibodies in blood, Day 1 up to 12 months|Objective Response Rate (ORR) as defined by IMWG response criteria, with ANV419 monotherapy, Day 1 up to 12 months|Objective Response Rate (ORR) as defined by IMWG response criteria, with ANV419 in combination with lenalidomide plus low-dose dexamethasone, Day 1 up to 12 months|Objective Response Rate (ORR) as defined by IMWG response criteria, with ANV419 in combination with daratumumab, Day 1 up to 12 months|Quality of life assessed with European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L), Day 1 up to 12 months|Quality of life assessed with European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Day 1 up to 12 months|Progression-free survival (PFS) according to IMWG response criteria, Day 1 up to 12 months|Duration of Response (DOR) according to IMWG response criteria, Day 1 up to 12 months|Clinical Benefit Rate (CBR) according to IMWG response criteria, Day 1 up to 12 months
The purpose of this multi-site, open-label, Phase 1 adaptive design study is to evaluate the safety, tolerability and preliminary efficacy of ANV419 as a monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab in patients aged 18 years or older with with relapsed or refractory Multiple Myeloma.